In colon adenocarcinoma, patients exhibiting RASSF1A promoter methylation demonstrated a significantly shorter DFS compared to those without methylation (mean: 17.4 vs. 30.1 months; HR = 2.25, 95% CI 1.27–3.99). This evidence concerns the gene RASSF1 and colon adenocarcinoma.